{"name":"EyeGene Inc.","slug":"eyegene-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"EG-MCV4","genericName":"EG-MCV4","slug":"eg-mcv4","indication":"Other","status":"phase_2"},{"name":"A: EG-COVID","genericName":"A: EG-COVID","slug":"a-eg-covid","indication":"Other","status":"phase_1"},{"name":"B: EG-COVID","genericName":"B: EG-COVID","slug":"b-eg-covid","indication":"Other","status":"phase_1"},{"name":"EG-COVID-001","genericName":"EG-COVID-001","slug":"eg-covid-001","indication":"Other","status":"phase_1"},{"name":"EG-COVII","genericName":"EG-COVII","slug":"eg-covii","indication":"Other","status":"phase_1"},{"name":"Treatment 5","genericName":"Treatment 5","slug":"treatment-5","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"EG-MCV4","genericName":"EG-MCV4","slug":"eg-mcv4","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"A: EG-COVID","genericName":"A: EG-COVID","slug":"a-eg-covid","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"B: EG-COVID","genericName":"B: EG-COVID","slug":"b-eg-covid","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EG-COVID-001","genericName":"EG-COVID-001","slug":"eg-covid-001","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EG-COVII","genericName":"EG-COVII","slug":"eg-covii","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Treatment 5","genericName":"Treatment 5","slug":"treatment-5","phase":"marketed","mechanism":"Treatment 5 works by","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQSHNudWFIYlZxaGhINDNkemRUYzRKbVYwaW1qWkhFeXFYeUVkSFFVaWI1NjNMM05oWFBSbFRodF9Gck96cms3NmJlVVVQX01KRTFnS2M4eHNON3lyT3F5TWZTT3lqNUxKYnE0NUVnUXdWM2pZV2FzTzhSRkFybWFEYjZoMXVMR1p0R3FpQ3ZzR0F2SVBkMUlrVVV2NzM2ZUJRU01kMF9pRFhZT1Y3UC04bDRsV1l3MkpYQlN3YzlvMUtIMDd4ZkxLQXFiUDJGdHZYLXRiVjJvMGVUdw?oc=5","date":"2026-04-01","type":"pipeline","source":"Barchart.com","summary":"COVID-19 Treatment Pipeline Shows Strong Momentum as 180+ Pharma Companies in the Race | DelveInsight - Barchart.com","headline":"COVID-19 Treatment Pipeline Shows Strong Momentum as 180+ Pharma Companies in the Race | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNcDZzMHZBNjdhcVZ1WnItNVlNbjRzWWFJdDZ1MlhSLWR5cjRJbUxFWU5zaXBqV042aEU1NUEyTXlkelJyZjhYNTZES1VCTTRla1NGSXlOMGxGR2tTbHQzZEhHNXppenJCb2ZEa2hJa0pYOTFrazVNeHZkeFFFdEYtTFZLWlIwZjdlZVMxdGZERFQ2aVJEWU9QclBITlJhSnc?oc=5","date":"2025-11-10","type":"deal","source":"BioPharma Dive","summary":"Lilly picks up an eye gene therapy in deal with MeiraGTx - BioPharma Dive","headline":"Lilly picks up an eye gene therapy in deal with MeiraGTx","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQVmh3MVNIODZLcFh4Q1YzUGRZc2tmam5CUnFUdVhiM0dhWFlpcW11N2JWMVhFQ3pZekJwODF0RkdkOGNCSjd6bUwwdGMtWkpoSS1ZZ3N3N0dkekhibFUwNFR3b3lORmlEZ3EzbktsZlJEWHN6UkFhWWh2cmNNdVhiR09iR2toVUY0Mm0yc2k3TEIyUTNwc1VLclZrWks4TzJMc0RaNnYyMEhuRXhkblhwakd4R1ExcEhEOXdocXFBdU1OZ0k?oc=5","date":"2025-11-03","type":"trial","source":"Fierce Biotech","summary":"Italian biotech AAVantgarde adds $141M series B to fund retinal disease gene therapy trials - Fierce Biotech","headline":"Italian biotech AAVantgarde adds $141M series B to fund retinal disease gene therapy trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNcjZqdFl1SlBHS1c3QlpwZTllZEo0WWhiT2FxS3NKUHNaTFduTUxCUTljUHRBQ0ZmVGtYc1BWOWx1aDAtSjFXbm54UlZkUzhHeDhxR1E2TEFRa1NJakNEWlBfRnBYdmxhaTRnRmJmR3MxdU04UXZpeEFIRXZqU2NwV1hSQloweUk?oc=5","date":"2024-09-19","type":"trial","source":"BioPharma Dive","summary":"4D Molecular data ‘bode well’ for eye gene therapy, but shares fall - BioPharma Dive","headline":"4D Molecular data ‘bode well’ for eye gene therapy, but shares fall","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE41ZlpWWEFkVmJCUl9vR1lrc0VjcWU2T0J3TmNDU1JaUi1YczJWcjQ2QjltcGIteV9hejB1V3YxcnZtRFNPUUtOVjVCUk84U3NoQnZLVm9WMUNJYUkzODBBLVdIYk51emlZQmtlRDBR0gFyQVVfeXFMTWE4dGxuVGhYZm1tOGZjaVAxZlhWSlFNTjZSd2h6bmdIRjVmZDVqTlJRYmV5cjh6b05wSmZzbHhJZ3UtcFNTbkpEdnY0eDdISnZ5bkZfTTJrMlVraWp1Q2dkNGcydXo0a3F1ZXBXcW5nand3?oc=5","date":"2024-07-03","type":"deal","source":"koreabiomed.com","summary":"EuBiologics license out EuMCV4 meningococcal vaccine to Eyegene - koreabiomed.com","headline":"EuBiologics license out EuMCV4 meningococcal vaccine to Eyegene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNNVBpVHl3N3BHai1ZamFmMHhib1J0SE5IVWZlbU9JdkF4cHVZQkdkUzFJdVM2Z0g4am1iX3ZNUjNKOTNVNXBtWk1zRGh2cWVPLURFd1N0WDBIYV9tUko3czFwV3FRZEtfODJCUUhmSW5kSElZWU02Tlk5QlExZFhHYUZqYm0ybWVERkdQVHB6cmlnSzA?oc=5","date":"2023-12-21","type":"pipeline","source":"BioPharma Dive","summary":"J&J bets bigger on MeiraGTx’s eye gene therapy - BioPharma Dive","headline":"J&J bets bigger on MeiraGTx’s eye gene therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5aeng5SGJmWlFjUExISWF4VW9CYlBKUC01MWc1X29QSFFldm1YQzlFRV9oXzNxT1ROSm5RNG1xSmFvQU52eXJsSkhib2FialhYbFpQZF9ISXVWU3BxWlNDOWgzX3ZZYUxBYUxGaHdR0gFyQVVfeXFMTndLQ0UzNjlSZWZYNkZmMU84b051WWNibHhCaGZ5cmY2eXp5RFlobURWVlJzTk9ISlhvX0FXSmk1TW81VzVsN0VmaGRfTFlIRGxGSGp0T1pabEZaMmh2b1FaM3pya205bTQwaVVxQWVrV3pR?oc=5","date":"2023-12-14","type":"pipeline","source":"koreabiomed.com","summary":"EyeGene initiates strategic R&D overhaul with BMI Korea becoming largest shareholder - koreabiomed.com","headline":"EyeGene initiates strategic R&D overhaul with BMI Korea becoming largest shareholder","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQOGlQNm9jQ0pyQVhjWEl5ZjQ4TXQwM1h4M282R29YNEgyc2FIS1VDYlQ2Vk5nWlVLcjRQMnhSM3QxSERwYU42aTNvcElUSWFoSlJjVXgwMzJjZWp6OW8waE9uZGpxU2ZJOVRheXktZHhWVHljWE5VeG9xZVMxejZzdDhSVWJhOHJRVlpUQU84dw?oc=5","date":"2023-06-12","type":"pipeline","source":"BioPharma Dive","summary":"Built from biotech parts, Beacon launches with $120M to develop eye gene therapies - BioPharma Dive","headline":"Built from biotech parts, Beacon launches with $120M to develop eye gene therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQSXVkRXE2OU42eXhyM2d3REhMcDVBamFpNkxmNXdGOWMyVUVTVG5LeEwzbllIMHU1dUc3WnQzcVBNZkdjeWJnOHZiV1ktb2lYcHctUEFWVmRPQ0dnT3lCTTNNUlR4alBqdE0wUlZwQnRvQmZPRmlueWM0SXlwRnpVVWhETlhraXFBalpSUQ?oc=5","date":"2022-04-06","type":"pipeline","source":"BioPharma Dive","summary":"Regeneron, in search of an eye gene therapy, turns to a young biotech - BioPharma Dive","headline":"Regeneron, in search of an eye gene therapy, turns to a young biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPcENiMDJOZW5XVGlvWUFOS05DSGJxbkk5aEh1YnVmNkpnTC1XbnhCRGRRODZKZEhCZmx1TU9HYW5RUEpGakpCdE9BeGE1S1FaRVlod3N6UVNvZkhMYTl4Yk1jWkVfZEgwamNud1c0akJkN2FBRk9kV3VIa1dsZ0JwX2dHWkZBZG5TSlZ6eXpjTjM?oc=5","date":"2020-12-02","type":"pipeline","source":"BioPharma Dive","summary":"J&J pushes further into eye gene therapy - BioPharma Dive","headline":"J&J pushes further into eye gene therapy","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_2":1,"phase_1":4,"marketed":1},"enrichmentLevel":0,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}